{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T16:21:55Z","timestamp":1795191715476,"version":"4.10.3"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fund for Scientific Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"State Agency of Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007461","name":"Fondation Brocher","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007461","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.lanepe.2026.101778","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:57:38Z","timestamp":1785434258000},"page":"101778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rebalancing innovation, affordability, and access for orphan drugs in the European Union"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7096-0467","authenticated-orcid":false,"given":"Hilde","family":"Stevens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Siotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micael","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Dewatripont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6221-4794","authenticated-orcid":false,"given":"Sanae","family":"Akodad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5540-5412","authenticated-orcid":false,"given":"Sam","family":"Daems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0222-7287","authenticated-orcid":false,"given":"Michel","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanepe.2026.101778_bib1","article-title":"US orphan drug act","volume":"381","author":"Ross","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.lanepe.2026.101778_bib2","series-title":"Orphan Medicines in the EU","year":"2025"},{"key":"10.1016\/j.lanepe.2026.101778_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-086527","article-title":"Global insight into rare disease and orphan drug definitions: a systematic literature review","volume":"15","author":"Abozaid","year":"2025","journal-title":"BMJ Open"},{"key":"10.1016\/j.lanepe.2026.101778_bib4","doi-asserted-by":"crossref","DOI":"10.2174\/0115701638379700250713040806","article-title":"The economics of drug development: a comparison between orphan and non-orphan drugs","volume":"23","author":"Gomase","year":"2026","journal-title":"Curr Drug Discov Technol"},{"key":"10.1016\/j.lanepe.2026.101778_bib5","article-title":"Rare diseases: still on the fringes of universal health coverage in Europe","volume":"37","author":"Tumien\u0117","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.lanepe.2026.101778_bib6","series-title":"Rare genetic Disease Therapy Becomes world's Most Expensive Drug at $4.25mn","author":"Barnes","year":"2024"},{"key":"10.1016\/j.lanepe.2026.101778_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/s43856-025-01344-1","article-title":"Impact of drug repurposing between 1985 and 2024 on pharmaceutical innovation","volume":"6","author":"Akodad","year":"2026","journal-title":"Commun Med"},{"key":"10.1016\/j.lanepe.2026.101778_bib8","series-title":"The Future of European Competitiveness","author":"Draghi","year":"2024"},{"key":"10.1016\/j.lanepe.2026.101778_bib9","series-title":"Commission Staff Working Document: Impact Assessment Report","year":"2023"},{"key":"10.1016\/j.lanepe.2026.101778_bib11","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-019-1078-5","article-title":"Comparing access to orphan medicinal products in Europe","volume":"14","author":"Zamora","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.lanepe.2026.101778_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1074512","article-title":"Orphan drugs' clinical uncertainty and prices: addressing allocative and technical inefficiencies in orphan drug reimbursement","volume":"14","author":"Eichler","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.lanepe.2026.101778_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c6471","article-title":"Orphan drug pricing may warrant a competition law investigation","volume":"341","author":"Roos","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.lanepe.2026.101778_bib14","series-title":"Pharma Package: Political Agreement on new EU Pharmaceutical Legislation","year":"2025"},{"key":"10.1016\/j.lanepe.2026.101778_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104096","article-title":"Reliable business case for repurposing of existing medicines requires key changes in government policies","volume":"29","author":"de Visser","year":"2024","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.lanepe.2026.101778_bib17","series-title":"Study to Support the Evaluation of the EU Orphan Regulation","author":"de Jongh","year":"2019"},{"key":"10.1016\/j.lanepe.2026.101778_bib18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s43441-025-00890-z","article-title":"Strategic drivers behind early withdrawal of orphan designations in the EU: a retrospective analysis (2000-2024)","volume":"60","author":"Bouwman","year":"2026","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.lanepe.2026.101778_bib19","series-title":"Economic Policy: Principles and Design","author":"Tinbergen","year":"1956"},{"key":"10.1016\/j.lanepe.2026.101778_bib20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(24)02719-3","article-title":"Making CAR T-cell therapies more affordable","volume":"405","author":"Senior","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.lanepe.2026.101778_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1642882","article-title":"Early access disparities in innovative therapies across the US, EU, China, and Japan","volume":"12","author":"Akodad","year":"2025","journal-title":"Front Med"},{"key":"10.1016\/j.lanepe.2026.101778_bib22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fmed.2019.00275","article-title":"The innovative medicines initiative \u2013 10 years of public-private collaboration","volume":"6","author":"Laverty","year":"2019","journal-title":"Front Med"},{"key":"10.1016\/j.lanepe.2026.101778_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1554948","article-title":"The innovative health initiative public-private partnership: a catalyst for big data-driven health research and innovation","volume":"12","author":"Vaudano","year":"2025","journal-title":"Front Med"},{"key":"10.1016\/j.lanepe.2026.101778_bib24","author":"Aghion"},{"key":"10.1016\/j.lanepe.2026.101778_bib25","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40258-021-00665-1","article-title":"The sandbox approach and its potential for use in health technology assessment: a literature review","volume":"19","author":"Leckenby","year":"2021","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.lanepe.2026.101778_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fmedt.2026.1729631","article-title":"Early and accelerated access programs for medical devices in the European Union: mapping regulatory derogations and national schemes","volume":"8","author":"Haon","year":"2026","journal-title":"Front Med Technol"},{"key":"10.1016\/j.lanepe.2026.101778_bib27","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41586-018-0217-9","article-title":"Targeted therapy in patients with PIK3CA-related overgrowth syndrome","volume":"558","author":"Venot","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.lanepe.2026.101778_bib28","series-title":"Anthropic Launches Claude Life Sciences for Research Using AI","author":"Cone","year":"2025"},{"key":"10.1016\/j.lanepe.2026.101778_bib29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.lanepe.2026.101778_bib30","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/d41573-023-00136-3","article-title":"A novel approach to boost drug development in paediatric oncology","volume":"22","author":"Daems","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.lanepe.2026.101778_bib31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.techsoc.2005.08.008","article-title":"Economic considerations in Cooperative Research and Development Agreements (CRADA): the case of Taxol, NIH, and technology transfer","volume":"28","author":"Hemphill","year":"2006","journal-title":"Technol Soc"},{"key":"10.1016\/j.lanepe.2026.101778_bib32","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1257\/aer.103.3.406","article-title":"Can financial engineering cure cancer?","volume":"103","author":"Fagnan","year":"2013","journal-title":"Am Econ Rev"},{"key":"10.1016\/j.lanepe.2026.101778_bib33","series-title":"Improving the Innovation\/Access Trade-off for Rare Diseases in the EU after Covid-19","author":"Dewatripont","year":"2022"},{"key":"10.1016\/j.lanepe.2026.101778_bib34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1162\/rest.89.1.88","article-title":"Pharmaceutical price controls and entry strategies","volume":"89","author":"Kyle","year":"2007","journal-title":"Rev Econ Stat"},{"key":"10.1016\/j.lanepe.2026.101778_bib35","series-title":"Europe's Biggest Multi-Country Access Alliance Picks Up the Pace","author":"Bruce","year":"2021"},{"key":"10.1016\/j.lanepe.2026.101778_bib36","author":"Rauland"},{"key":"10.1016\/j.lanepe.2026.101778_bib37","series-title":"BeNeLuxA Initiative Archive","year":"2024"},{"key":"10.1016\/j.lanepe.2026.101778_bib38","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1257\/pandp.20201017","article-title":"Advance market commitments: insights from theory and experience","volume":"110","author":"Kremer","year":"2020","journal-title":"AEA Pap Proc"},{"key":"10.1016\/j.lanepe.2026.101778_bib39","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1287\/mnsc.2021.4163","article-title":"Designing advance market commitments for new vaccines","volume":"68","author":"Kremer","year":"2022","journal-title":"Manage Sci"},{"key":"10.1016\/j.lanepe.2026.101778_bib40","article-title":"New opportunities for accessing promising non-oncological orphan drugs","volume":"52","author":"Hollak","year":"2025","journal-title":"Lancet Reg Health Eur"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226001900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226001900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T15:54:34Z","timestamp":1795190074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776226001900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":38,"alternative-id":["S2666776226001900"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101778","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rebalancing innovation, affordability, and access for orphan drugs in the European Union","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101778","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101778"}}